Canaccord Genuity
Canaccord Genuity 41st Annual Growth Conference Registration for Canaccord Genuity 41st Annual Growth Conference Click here Symbols – CSE: BRAX OTC: BRAXF FWB: 496
Global Investment Conference
H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Registration for H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Click here Symbols – CSE: BRAX OTC: BRAXF FWB: 496
First Quarter 2022 Financial Results
Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientific’s network of clinics, including a Ketamine trial for Bipolar Depression, a Ketamine trial to rapidly reduce suicidality, and the first multiple-dose psilocybin trial to combat treatment-resistant depression TORONTO, ONTARIO Aug. 30, 2021 – Braxia Scientific Corp. (“Braxia Scientific,” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal first-quarter results for the three-month period ending June 30, 2021. Complete financial statements along with related management discussion and analysis can be...
Landmark Clinical Trial
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
CORPORATE UPDATE AND REPORTING
BRAXIA SCIENTIFIC PROVIDES CORPORATE UPDATE AND REPORTS FISCAL FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS TORONTO, ONTARIO July 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com. Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry. Braxia Scientific successfully expanded its network of multidisciplinary clinics to four in 2021, with one of very few private clinics approved in Canada to provide innovative intravenous (IV) Ketamine treatments to...
EXPERIMENTAL MEDICINE IN PSYCHIATRY
BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021 TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021. Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the...
PSYCH INVESTOR SUMMIT
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT PSYCH INVESTOR SUMMIT ON JULY 7, 2021 TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021. Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will...
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM TO DEVELOP NEW GENERATION OF QUALIFIED PHYSICIANS, PSYCHOTHERAPISTS AND PSYCHOLOGISTS FOR MENTAL HEALTH TORONTO, ONTARIO June 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce it has launched its psilocybin-assisted clinical therapy training program. Through this program, Braxia will develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective psilocybin-assisted therapy for patients with depression. The therapists will participate in the provision of psychotherapy in upcoming clinical trials at Braxia evaluating the safety and efficacy of psilocybin in depression. The Company anticipates that, pending regulatory approval of psilocybin, therapists would also be...
TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021
Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 Application Deadline: July 11, 2021 Tentative Program Start Date: September 2021 (pandemic permitting) A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical...
ENROLLMENT FOR SEPTEMBER 2021
BRAXIA INSTITUTE TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021 Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical care, if psilocybin...
WEBCAST ALERT: H.C. WAINWRIGHT & CO.
WEBCAST ALERT: H.C. WAINWRIGHT VIRTUAL CONFERENCE PRESENTATION WEBCAST ALERT Dr. Roger McIntyre @ H.C. Wainwright Virtual Conference Presentation The Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry Tune in Live on Thursday, 6/17 at 2:00 PM (Eastern Standard Time) Webcast link is closed. Symbols – CSE: BRAX OTC: BRAXF FWB: 496